MedTrace Logo

Bioavailability Study of Psilocybin in Normal Adults

NCT05467761 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2023-05-15

No results posted yet for this study

Summary

The purpose of this research study is to compare an oral dose of psilocybin and an intravenous (IV) infusion of psilocybin to assess differences in how the drug is absorbed by the body, the psychedelic experience, and any side effects when taken by healthy adult participants. Participants can expect to be in the study for approximately 12 weeks.

Conditions

  • Healthy

Interventions

DRUG

Oral Psilocybin

25mg orally

DRUG

IV Psilocybin

5mg intravenously

Sponsors & Collaborators

  • TRYP Therapeutics

    collaborator INDUSTRY

  • University of Wisconsin, Madison

    lead OTHER

Principal Investigators

  • Christopher Nicholas, PhD · University of Wisconsin, Madison

  • Paul Hutson, PharmD · University of Wisconsin, Madison

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
25 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-06-30
Primary Completion
2024-03-31
Completion
2024-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05467761 on ClinicalTrials.gov